Treatment Algorithm Insight Series

Quantifying Lines of Therapy through Primary Research and Patient-Level Data

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PHARMetrics to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

The new Treatment Algorithms Insight Series delivers real value by examining physicians' actual prescribing behavior as they initiate therapy and move through second- and third-line choices. Our analysis is driven by the largest and most complete longitudinal patient-level database available. This database examines the prescribing practices for 55 million patients from more than 80 health plans, providing the most representative sample of U.S. treatment practice. For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides the following:

• Qualitative diagnosis and referral patterns for the United States based on thought leader input and guideline recommendations.
• Quantitative treatment algorithms based on patient-level claims data.
• Product share (class and specific compound level) within each line of therapy (1st, 2nd, 3rd line).
• Practicing physician opinion on why specific drugs are chosen for certain patient populations.
• Discussion of key drug combinations (including add versus switch patterns) by lines of therapy.
• Progression of therapy from key 1st line products (e.g., initial treatment w/ Lipitor to 2nd line, 3rd line; initial treatment with Zocor to 2nd line, 3rd line).
• Pathway to key therapies from previous therapies (e.g., how much Avandamet use is preceded by metformin, Avandia, or both as single products?).
• Qualitative analysis of 2-year forecast incorporating practicing physician sentiment towards upcoming launches, changes in reimbursement, etc.

To provide this level of analysis, we first examine the patient-level data and then interview 150 physicians, including PCPs and the appropriate specialists, to discover the reasoning behind the actual prescribing behavior. Our interviews clarify the treatment patterns and tell you why a drug achieves its patient share within each line of therapy.  

Key Benefits

The Treatment Algorithms Insight Series gives you an edge in shaping your market-driven business decisions. Reports in this series allow users to:

• Understand current treatment patterns and anticipate future market dynamics.
• Drive product growth through accurate knowledge of your product's positioning among the lines of therapy and why physicians use it at that point.
• Target specific competitors that are preceding or following your product and benefit from actionable analysis of the path to treatment and physicians' decision parameters.
• Develop more sophisticated market-forecasting patient-flow models based on the unique, accurate information we provide regarding the percentage of patients receiving your product at specific stages in the line of therapy.

Our most recent Treatment Algorithms:

Treatment Algorithm Insight Series: Parkinson's Disease

Treatment Algorithm Insight Series: Schizophrenia

Treatment Algorithm Insight Series: Generalized Anxiety Disorder

Treatment Algorithm Insight Series: Major Depression

Treatment Algorithm Insight Series: Dyslipidemia

Download our Treatment Algorithms brochure

View 2008 Treatment Algorithms titles